|
| 38039965 | A road map for the treatment of pediatric diffuse midline glioma. | Cancer Cell | 2024 |
| 36609807 | Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial. | J Neurooncol | 2023 |
| 36054558 | A novel serum extracellular vesicle protein signature to monitor glioblastoma tumor progression. | Int J Cancer | 2023 |
| 37921974 | Correction to: Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses. | J Neurooncol | 2023 |
| 37728779 | Undetected pseudoprogressions in the CeTeG/NOA-09 trial: hints from postprogression survival and MRI analyses. | J Neurooncol | 2023 |
| 37803478 | Assessment of technical and clinical utility of a bead-based flow cytometry platform for multiparametric phenotyping of CNS-derived extracellular vesicles. | | 2023 |
| 37787906 | The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial. | J Neurooncol | 2023 |
| 36905695 | Gliosarcoma with extensive extracranial metastatic spread and familial coincidence: A case report. | | 2023 |
| 37313277 | Distress in Neuro-Oncology Patients and Its Implications for Communication. | | 2023 |
| 35704157 | Prognostic impact of obesity in newly-diagnosed glioblastoma: a secondary analysis of CeTeG/NOA-09 and GLARIUS. | J Neurooncol | 2022 |
| 34502122 | Extracellular Vesicle Separation Techniques Impact Results from Human Blood Samples: Considerations for Diagnostic Applications. | Int J Mol Sci | 2021 |
| 33692626 | Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells. | OncoTargets and Therapy | 2021 |
| 33113214 | MGMT promoter methylation analysis for allocating combined CCNU/TMZ chemotherapy: Lessons learned from the CeTeG/NOA-09 trial. | Int J Cancer | 2021 |
| 33003586 | Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature. | Int J Mol Sci | 2020 |
| 31828428 | Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. | J Cancer Res Clin Oncol | 2020 |
| 31325144 | Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. | J Neurooncol | 2019 |
| 32257278 | Corticosteroid-responsive aseptic meningitis during regorafenib treatment. | Neurooncol Pract | 2019 |
| 31089718 | Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis. | Neuro Oncol | 2019 |
| 31488360 | Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial. | Lancet Oncol | 2019 |
| 30782343 | Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. | Lancet | 2019 |
| 29808316 | Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial. | J Cancer Res Clin Oncol | 2018 |
| 29754968 | Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma. | J Clin Neurosci | 2018 |
| 29121274 | Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. | Neuro Oncol | 2018 |
| 27891815 | Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma. | Cancer Med | 2017 |
| 28437838 | Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma. | Genes Chromosomes Cancer | 2017 |
| 29039591 | Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease. | Oncol Rep | 2017 |
| 27556362 | Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. | Oncotarget | 2016 |
| 27100354 | Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. | J Cancer Res Clin Oncol | 2016 |
| 27318492 | The earlier the better? Bevacizumab in the treatment of recurrent MGMT-non-methylated glioblastoma. | J Cancer Res Clin Oncol | 2016 |
| 26673798 | Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET. | Clin Cancer Res | 2016 |
| 26516630 | Reduction of microbleeds by immunosuppression in a patient with Aβ-related vascular inflammation. | Neurology: Neuroimmunology and NeuroInflammation | 2015 |
| 24553142 | Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. | Nature | 2014 |
| 22832583 | Dissecting the genomic complexity underlying medulloblastoma. | Nature | 2012 |